Recursion Pharmaceuticals, Inc. - stock earnings
RXRX Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023Q4 | -93.0 million USD | 10.9 million USD |
| 2023Q3 | -93.0 million USD | 10.1 million USD |
| 2023Q2 | -76.7 million USD | 11.0 million USD |
| 2023Q1 | -60.8 million USD | 12.1 million USD |
| 2022Q4 | -57.5 million USD | 13.7 million USD |
| 2022Q3 | -58.3 million USD | 13.1 million USD |
| 2022Q2 | -65.5 million USD | 7.7 million USD |
| 2022Q1 | -56.0 million USD | 5.3 million USD |
| 2021Q4 | -64.9 million USD | 2.5 million USD |
| 2021Q3 | -47.4 million USD | 2.5 million USD |
| 2021Q2 | -43.4 million USD | 2.5 million USD |
| 2021Q1 | -30.7 million USD | 2.5 million USD |
| 2020Q4 | -25.8 million USD | 2.6 million USD |
| 2020Q3 | -23.9 million USD | 862000 USD |
| 2020Q2 | -18.9 million USD | 186000 USD |
| 2020Q1 | -18.4 million USD | 60000 USD |
RXRX Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -328.1 million USD | 44.6 million USD |
| 2022 | -239.4 million USD | 39.7 million USD |
| 2021 | -178.1 million USD | 10.0 million USD |
| 2020 | -87.9 million USD | 3.4 million USD |
| 2019 | -62.5 million USD | 1.7 million USD |
RXRX
Price: $8.94
52 week price:
Earnings Per Share: -1.58 USD
P/E Ratio: -6.25
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Volume: 732400
Market Capitalization: 2.1 billion